durvalumab
astrazeneca
['durvalumab', 'topaz-1']
 in previously untreated advanced biliary tract #cancer, durvalumab plus gemcitabine and cisplatin demonstrated statistically significant prolonged overall survival versus placebo plus gemcitabine and cisplatin. more about the topaz-1 trial: #asco22 
NEJM Evidence, a new journal from NEJM Group, presents innovative #OriginalResearch and fresh, bold ideas in #ClinicalTrial design and clinical decision-making.